Physician profile
Daniel P Golightly
NPI 1508955071
$1,885.68
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $582 · 2021: $469 · 2022: $305 · 2023: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.17 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $241.65 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $239.20 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $172.07 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.99 | 2022-2023 | |
| Lundbeck LLC | $123.21 | 2019-2021 | |
| Orexo US, INC. | $89.50 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $74.32 | 2019-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $64.03 | 2019-2022 | |
| Alkermes, INC. | $41.60 | 2022 | |
| Bausch Health US, LLC | $36.08 | 2020-2021 | |
| Axsome Therapeutics, INC. | $32.93 | 2023 | Auvelity |
| Eisai INC. | $31.12 | 2020 | |
| Supernus Pharmaceuticals, INC. | $25.93 | 2023 | Qelbree |
| Allergan, INC. | $20.98 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $19.97 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.87 | 2020 | |
| Merck Sharp & Dohme LLC | $17.28 | 2021 | |
| Noven Therapeutics, LLC | $15.90 | 2023 | Secuado |
| Ironshore Pharmaceuticals INC. | $15.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Golightly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.